At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Not Yet Opened 04-14 16:08:20
17.310
-0.190
-1.09%
High17.600Low16.900Vol1.24M
Open17.490D1 Closing17.500Amplitude4.00%
Mkt Cap18.37BTradable Cap18.37BTotal Shares1.06B
T/O21.37MT/O Rate0.12%Tradable Shares1.06B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Analysts Are Optimistic We'll See A Profit From Ascletis Pharma Inc. (HKG:1672)
Simply Wall St.  ·  04-09
Analysts Are Optimistic We'll See A Profit From Ascletis Pharma Inc. (HKG:1672)
ASCLETIS-B Maintains Stable Share Base in March; No New Issuance, Public Float Fully Compliant
Bulletin Express  ·  04-08
ASCLETIS-B Maintains Stable Share Base in March; No New Issuance, Public Float Fully Compliant
ASCLETIS-B Advances Clinical Development of Fixed-Dose Combination ASC30_39 for Obesity Treatment
Stock News  ·  04-07
ASCLETIS-B Advances Clinical Development of Fixed-Dose Combination ASC30_39 for Obesity Treatment
BRIEF-Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Reuters  ·  04-07
BRIEF-Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Ascletis Accelerates Obesity Pipeline with First-in-Class Oral GLP-1/Amylin Fixed-Dose Combo; IND Targeted for Q3 2026
Bulletin Express  ·  04-07
Ascletis Accelerates Obesity Pipeline with First-in-Class Oral GLP-1/Amylin Fixed-Dose Combo; IND Targeted for Q3 2026
Ascletis Pharma Inc - Expects Ind Submission to FDA for Asc30_39 Fdc in Q3 2026
THOMSON REUTERS  ·  04-07
Ascletis Pharma Inc - Expects Ind Submission to FDA for Asc30_39 Fdc in Q3 2026
Ascletis targets Q3 2026 FDA IND filing for oral obesity combo ASC30_39 tablet
Reuters  ·  04-07
Ascletis targets Q3 2026 FDA IND filing for oral obesity combo ASC30_39 tablet
Ascletis Pharma's Loss Widens 20% in 2025; Shares Rise 5%
MT Newswires Live  ·  04-01
Ascletis Pharma's Loss Widens 20% in 2025; Shares Rise 5%
BRIEF-Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Reuters  ·  04-01
BRIEF-Ascletis Pharma FY Loss Attributable Rmb359.9 Million
ASCLETIS-B Reports Annual Loss Attributable to Shareholders of 360 Million Yuan, Widening 19.6% Year-on-Year
Stock News  ·  03-31
ASCLETIS-B Reports Annual Loss Attributable to Shareholders of 360 Million Yuan, Widening 19.6% Year-on-Year
Ascletis Pharma Inc - FY Loss Attributable RMB359.9 Mln
THOMSON REUTERS  ·  03-31
Ascletis Pharma Inc - FY Loss Attributable RMB359.9 Mln
HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%
Tiger Newspress  ·  03-27
HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%
HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.
Tiger Newspress  ·  03-26
HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.
HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%
Tiger Newspress  ·  03-24
HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%
BRIEF-Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026
Reuters  ·  03-17
BRIEF-Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026
Ascletis targets Q3 2026 FDA IND filing for ASC39 oral obesity tablets
Reuters  ·  03-17
Ascletis targets Q3 2026 FDA IND filing for ASC39 oral obesity tablets
ASCLETIS-B Selects Oral Amylin Receptor Agonist ASC39 as Clinical Candidate, Demonstrating Eloralintide-Like Selectivity and Efficacy in Preclinical Models
Stock News  ·  03-17
ASCLETIS-B Selects Oral Amylin Receptor Agonist ASC39 as Clinical Candidate, Demonstrating Eloralintide-Like Selectivity and Efficacy in Preclinical Models
Ascletis Pharma Inc - Expects to Submit Ind Application to U.S. FDA for Asc39 Oral Tablets in Q3 2026
THOMSON REUTERS  ·  03-17
Ascletis Pharma Inc - Expects to Submit Ind Application to U.S. FDA for Asc39 Oral Tablets in Q3 2026
Ascletis says ASC39 delivered 6.6% placebo-adjusted weight loss in obese rats and targets US FDA IND filing in Q3 2026
Reuters  ·  03-17
Ascletis says ASC39 delivered 6.6% placebo-adjusted weight loss in obese rats and targets US FDA IND filing in Q3 2026
HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.
Tiger Newspress  ·  03-17
HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--